BMEYE B.V. Completes EUR 6 Million Series B Financing Round

New Investors Earlybird and 360 Capital Partners led the Round

AMSTERDAM, October 8 /PRNewswire/ -- BMEYE B.V., the non-invasive
cardiovascular monitoring company, today announced the successful completion
of its Series B financing round, raising EUR 6 million. New investors
Earlybird, who led this round, and 360 Capital Partners participated in the
financing, along with other existing BMEYE shareholders as LSP (Life Sciences
Partners) and Techfund.
BMEYE has successfully been selling Nexfin(TM), an FDA and CE approved
cardiovascular monitor which uses an easy to apply finger sensor to produce
accurate beat-to-beat, non-invasive blood pressure and cardiac output data
displayed on an intuitive touch screen. Proceeds from the financing will
support the accelerated growth program of the company based on further
product introductions and development of the sales channel.
"We are pleased to have completed this financing round, especially given
today's challenging economic climate," said Rob de Ree, BMEYE's Chief
Executive Officer. "This is a solid recognition of the quality of the BMEYE
team and our success since the introduction of the Nexfin monitor, with
highly regarded new and existing investors participating."
"We never experienced such positive response by potential customers in
our Due Diligence work. BMEYE introduced truly a breakthrough technology in
non-invasive, beat-to-beat cardiovascular monitoring in Europe and the United
States," comments Thom Rasche, Partner at Earlybird, who will resume a board
seat. "The technology is clinically validated, widely published and the
market potential is very large. The main application areas are in the
fast-growing segments of cardiology, emergency and critical care," adds Diana
Saraceni, Partner at 360 Capital Partners who will as well resume a board
position.
BMEYE B.V. was founded in 2005. In 2006 the company closed the Series A
round with LSP as the lead investor.
"Over the past 3 years, BMEYE has developed from an R&D based group to a
fully commercial, professional organization," says Rene Kuijten, LSP's board
member. "With the addition of two qualified investors and EUR 6 million in
new equity funding, the company is well equipped to continue its growth path."
About BMEYE B.V.
Mission: BMEYE B.V. is the premier provider and will set the standard of
non-invasive, beat-to-beat, user-friendly cardiovascular monitoring systems,
to improve patient care and reduce healthcare costs.
BMEYE B.V., a Dutch-based company in Amsterdam, develops and markets
innovative medical technology with broad applications in a variety of
clinical settings. The focus of BMEYE B.V. is on user friendly, non-invasive
hemodynamic cardiovascular monitoring. The Nexfin(TM) family of monitors use
an easy to apply finger sensor to produce accurate beat-to-beat, non-invasive
blood pressure and cardiac output data displayed on an intuitive touch screen.
Patents pending. For more information please check our website at
http://www.bmeye.com.
About Earlybird
Earlybird Venture Capital is one of the most successful European venture
investors. Currently, Earlybird manages over 400 million Euros of assets for
an international investor base. Earlybird invests in innovative, fast growing
companies with outstanding management teams and high growth potential on
international markets. Earlybird's portfolio currently includes more than 25
companies in seven countries (Austria, Germany, Italy, Netherlands,
Switzerland, UK and USA). Since inception Earlybird has invested in 58
companies. Besides several successful trade sales, Earlybird has led six
companies to an IPO at four different European exchanges.
Further information is available at http://www.earlybird.com or follow us
on Twitter: EarlybirdVC
About 360 Capital Partners
360 Capital Partners is a Venture Capital firm, investing in Innovation
at full scale, in Europe. 360 Capital Partners is managed by a consolidated
team which has cumulated 50+ years of Venture Capital experience in investing
in, following-up and/or exiting from over 60 companies and which have more
than EUR200 million under management, provided by top tier international
investors. 360 Capital Partners leverages an important international network,
it co-invested with major international Venture Capital funds in 10 countries
and have proven a top quartile track record as individuals and as a team in
very different economic environments
About LSP
LSP (Life Sciences Partners) is a leading independent European investment
firm, providing financing to private and public life-science companies. Since
the late 1980s, LSP's management has invested in a large number of highly
innovative enterprises, many of which have grown to become leaders of the
global life-science industry. For example, LSP was a founding investor in
Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million
under management and offices in Amsterdam, Munich and Boston, LSP is one of
Europe's largest and most experienced life-science investors.
Further information is available at http://www.lspvc.com.
SOURCE BMEYE B.V.

Contact information: Rob de Ree, CEO BMEYE, rob.deree@bmeye.com, BMEYE,
Headquarters, Academic, Medical Center, Suite, K2-245, Meibergdreef 9, 1105 AZ
Amsterdam, The Netherlands, Phone: +31(0)205-665838; Daniela von Wedel,
vonwedel@earlybird.com, Earlybird Venture Capital, Van-der-Smissen Str. 3,
22767 Hamburg, Germany, Phone: +49-40-432941-0; Diana Saraceni,
diana.saraceni@360capitalpartners.com, general partner 360 Capital Partners,
Via Brisa 3 - Milan, Italy, Phone +39-02-36-56-09-50; Dr. Rene R. Kuijten,
rkuijten@lspvc.com, General Partner LSP, Johannes Vermeerplein 9, 1071 DV
Amsterdam, The Netherlands, Phone: +31206645500